Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston biotech with visual AI TIMING platform analyzing individual cell behaviors in nanowell grids; $5.78M raised plus NIH STTR grant targeting CAR-T quality release and drug discovery screening.
CellChorus is a Houston-based biotechnology company developing the TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform — a visual AI system that analyzes individual cell behaviors over time in nanoscale grid arrays to characterize how cells interact, move, and function, enabling drug developers and cell therapy manufacturers to optimize their biologics and cell therapies with unprecedented single-cell resolution. Founded in 2021 and backed with $5.78 million in equity funding plus $3.4 million in non-dilutive grants including a $2.5 million NIH STTR Fast-Track grant in partnership with University of Houston, CellChorus serves biotech researchers, cell therapy manufacturers, and pharmaceutical companies.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.